CXCL10 and COVID-19: Patients with mild COVID-19 who were treated with the intramuscular administration of collagen-PVP showed an improvement in the disease during the first week of treatment [42], where the effects were associated with reductions in IP-10, IL-8, and macrophage colony stimulating factor (M-CSF) [34]; these results are consistent with our preliminary findings, obtained through microarray assays performed in fibroblast and monocyte cultures treated with 3% collagen-PVP, where some important pathways related to inflammation, apoptosis, and ECM receptor signalling were modulated.